“We want an agreement, and we clearly state that companies are willing to commit to binding mandatory obligations to share, whether it's with the WHO, GAVI UNICEF or UNITAID, for rollout to those with the highest medical needs, provided the system is workable.” – International Federation of Pharmaceutical Manufacturers and Associations’ outgoing director general Thomas Cueni on the WHO pandemic treaty. Find out more: 'Don’t Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas-Cueni
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
More from International
More from Geography
• By
The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
• By
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.